loadpatents
name:-0.028463125228882
name:-0.023082971572876
name:-0.00042295455932617
Rock; Michael Harold Patent Filings

Rock; Michael Harold

Patent Applications and Registrations

Patent applications and USPTO patent grants for Rock; Michael Harold.The latest application filed is for "novel polymorphic form of n-[2-(6-fluoro-lh-indol-3-yl)ethyl]-3-2,2,3,3-tetrafluoropropoxy)benzylam- ine hydrochoride for the treatment of alzheimer's".

Company Profile
0.24.29
  • Rock; Michael Harold - Frederiksberg C DK
  • Rock; Michael Harold - Hvidovre DK
  • Rock; Michael Harold - Fredirksberg C N/A DK
  • Rock; Michael-Harold - Valby DK
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Polymorphic form of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzyla- mine hydrochloride for the treatment of Alzheimer's disease
Grant 10,071,963 - Andersen , et al. September 11, 2
2018-09-11
Novel Polymorphic Form of N-[2-(6-fluoro-lH-indol-3-yl)ethyl]-3-2,2,3,3-tetrafluoropropoxy)benzylam- ine hydrochoride for the treatment of Alzheimer's
App 20170152227 - Andersen; Kristine Birklund ;   et al.
2017-06-01
Processes for the manufacture of a pharmaceutically active agent
Grant 9,382,205 - Therkelsen , et al. July 5, 2
2016-07-05
1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
App 20160083359 - Bang-Andersen; Benny ;   et al.
2016-03-24
Process for preparing 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salt thereof
Grant 9,101,626 - Faldt , et al. August 11, 2
2015-08-11
Process for preparing 1-[2-(2,4-dimethylphenysulfanyl)-pheny]piperazine or pharmaceutically acceptable salt thereof
Grant 9,095,588 - Faldt , et al. August 4, 2
2015-08-04
Processes For The Manufacture Of A Pharmaceutically Active Agent
App 20150080584 - Therkelsen; Frans ;   et al.
2015-03-19
1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment
App 20140371453 - Faldt; Andre ;   et al.
2014-12-18
Processes for the manufacture of a pharmaceutically active agent
Grant 8,901,318 - Therkelsen , et al. December 2, 2
2014-12-02
1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment
App 20140256943 - Faldt; Andre ;   et al.
2014-09-11
Crystalline forms of a pharmaceutical compound
Grant 8,729,065 - Rock , et al. May 20, 2
2014-05-20
Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
Grant 8,598,348 - Nicolajsen , et al. December 3, 2
2013-12-03
Processes For The Manufacture Of A Pharmaceutically Active Agent
App 20130245281 - Therkelsen; Frans ;   et al.
2013-09-19
Processes for the manufacture of a pharmaceutically active agent
Grant 8,461,353 - Therkelsen , et al. June 11, 2
2013-06-11
Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
App 20120004409 - Nicolajsen; Henrik Vigan ;   et al.
2012-01-05
Crystalline forms of a pharmaceutical compound
Grant 8,076,320 - Rock , et al. December 13, 2
2011-12-13
Processes For The Manufacture Of A Pharmaceutically Active Agent
App 20110152539 - Therkelsen; Frans ;   et al.
2011-06-23
Crystalline Forms of a Pharmaceutical Compound
App 20110124629 - Rock; Michael Harold ;   et al.
2011-05-26
Crystalline Base Of Escitalopram And Orodispersible Tablets Comprising Escitalopram Base
App 20110046218 - Dancer; Robert ;   et al.
2011-02-24
1- [2- (2,4-dimethylphenylsulfanyl)-phenyl] Piperazine As A Compound With Combined Serotonin Reuptake, 5-ht3 And 5-ht1a Activity For The Treatment Of Cognitive Impairment
App 20100297240 - Bang-Andersen; Benny ;   et al.
2010-11-25
Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
Grant 7,834,201 - Dancer , et al. November 16, 2
2010-11-16
Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
Grant 7,723,533 - Dancer , et al. May 25, 2
2010-05-25
Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
Grant 7,560,576 - Dancer , et al. July 14, 2
2009-07-14
Method For The Preparation Of Citalopram
App 20090088469 - Petersen; Hans ;   et al.
2009-04-02
Crystalline Base Of Escitalopram And Orodispersible Tablets Comprising Escitalopram Base
App 20080161584 - Dancer; Robert ;   et al.
2008-07-03
Crystalline Base Of Escitalopram And Orodispersible Tablets Comprising Escitalopram Base
App 20080161388 - Dancer; Robert ;   et al.
2008-07-03
Method for the preparation of citalopram
Grant 7,271,273 - Petersen , et al. September 18, 2
2007-09-18
Crystalline forms of a pharmaceutical compound
App 20070191339 - Rock; Michael Harold ;   et al.
2007-08-16
Crystalline Base Of Escitalopram And Orodispersible Tablets Comprising Escitalopram Base
App 20070021499 - Dancer; Robert ;   et al.
2007-01-25
Method for the preparation of citalopram
App 20060079700 - Petersen; Hans ;   et al.
2006-04-13
Method for the preparation of citalopram
Grant 6,768,011 - Rock , et al. July 27, 2
2004-07-27
Method for the preparation of citalopram
Grant 6,750,358 - Petersen , et al. June 15, 2
2004-06-15
Arylsulphonamides and analogues
Grant 6,727,279 - Mittendorf , et al. April 27, 2
2004-04-27
Method for the preparation of citalopram
App 20030114692 - Petersen, Hans ;   et al.
2003-06-19
Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
Grant 6,573,278 - Mittendorf , et al. June 3, 2
2003-06-03
Method for the preparation of citalopram
App 20030092761 - Rock, Michael Harold ;   et al.
2003-05-15
Method for the preparation of citalopram
App 20030083508 - Petersen, Hans ;   et al.
2003-05-01
Novel arylsulphonamides and analogues
App 20030073727 - Mittendorf, Joachim ;   et al.
2003-04-17
Aryl sulphonamide amino acid esters and analogues
Grant 6,545,050 - Mittendorf , et al. April 8, 2
2003-04-08
Method For The Preparation Of Citalopram
App 20020198391 - Petersen, Hans ;   et al.
2002-12-26
Method for the preparation of citalopram
App 20020177722 - Rock, Michael Harold ;   et al.
2002-11-28
Aryl sulphonamides and analogues
Grant 6,469,054 - Mittendorf , et al. October 22, 2
2002-10-22
Method for the preparation of citalopram
App 20020077353 - Petersen, Hans ;   et al.
2002-06-20
Arylsulfonamides and analogues
App 20020072529 - Mittendorf, Joachim ;   et al.
2002-06-13
Method for the preparation of citalopram
App 20020061925 - Petersen, Hans ;   et al.
2002-05-23
Method for the preparation of citalopram
App 20020035277 - Rock, Michael Harold ;   et al.
2002-03-21
Method for the preparation of citalopram
App 20020004604 - Petersen, Hans ;   et al.
2002-01-10
Method for the preparation of citalopram
App 20010027256 - Petersen, Hans ;   et al.
2001-10-04
Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
Grant 6,262,112 - Mittendorf , et al. July 17, 2
2001-07-17
Process for preparing pentafluoropentanol
Grant 6,002,053 - Rock , et al. December 14, 1
1999-12-14

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed